P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH by S. Saraf, R. C. Brown, R. W. Hagar, M. Idowu, I. Osunkwo, T. A. Kalfa, F. A. Kuypers, J. Geib, P. Schroeder, E. Wu, P. Kelly, M. J. Telen

Get full text